MVP.ASX Releases Q1 FY27 Quarterly Report
Key points
- European in-market volume growth of 37% for Penthrox
- Paediatric label approval driving increased Penthrox use in Europe
- Penthrox volume growth of 24% in Australian hospital segment
Full summary
Medical Developments International Ltd (ASX: MVP) released its Appendix 4C and Quarterly Activity Report for the quarter ended 30 September 2026. The report highlighted a 37% growth in European in-market volume for Penthrox, driven by the recently approved paediatric label. Penthrox volume in the Australian hospital segment grew by 24%. Despite a slight decrease in overall revenue, the company maintained operational and financial momentum, with improved operating cashflows due to tight cost management.
Outlook
The company expects higher Penthrox demand in FY27, stable Respiratory segment demand, and non-recurrence of inventory stocking benefits.
Summary generated by a large language model. Please interpret with care.